C-Booth Innovations Presents
12-Lead
An Elevated form of ECG Technology – 12-lead continuous cardiac monitoring with radiolucent design for uninterrupted imaging and AHA-compliant electrode placement.
Better Data Faster
12-Lead Wearable
The EXG™ platform revolutionizes cardiac monitoring with rapid deployment, improved electrode placement accuracy, and seamless integration into existing workflows.
Continuous Monitoring
Continuous diagnostic monitoring, expandable to 18-lead
3-Day Wear
3-day wear can tolerate diaphoresis and showering
Radiolucent
Radiolucent for uninterrupted imaging in Cath Lab
See the EXG™ Platform in Action
Watch our demonstration video to see how easy deployment can be
Old Versus New
See how the EXG™ platform solves every traditional ECG challenge
Traditional ECG Problems
Legacy system limitations
- User Error – Incorrect and inconsistent node placement
- Complexity discourages use (equipment failure and protocol violations)
- Poor tolerance to uncooperative patient
- Poor tolerance to motion/transit
- Environmental limitations
- Poor Adhesion (general)
- Poor Adhesion (under diaphoresis)
- Time to apply discourages use
- Burdensome to apply and disentangle
- Risk for cross infection
- High level of waste
- Lower signal quality
- Requires additional cables for right and posterior
New EXG™ Solutions
Modern innovations that work
- Accurate node placement
- Rapid deployment
- Broad anthropomorphic scale
- Single connection point
- Radiolucency
- 1-time application (consistent baseline)
- Reduced motion artifacts (high SNR)
- Compatible with all in-market systems
- AHA-compliant node placement
- Continuous 12-lead monitoring
- Disposable
- Parity or better cost
- Seamless departmental transitions
- Enhanced system efficiency
- Immediate EKG acquisition during critical ROSC post CPR
Same Patient, 3 Different Readings
3 ECGs performed by three licensed EMS providers on the same patient demonstrate the electrode misplacement problem.
Each reading shows different results due to inconsistent electrode placement
Clinical Impact
Proven results in real-world cardiac care settings
Global population living with heart and circulatory diseases (British Heart Foundation 2023)
30% of Americans defined as clinically obese (CDC 2022)
Global deaths attributable to heart and circulatory diseases (British Heart Foundation 2023)
Annual heart attack wrongful death exposure (NEWMAN ET AL. 2022) (1.5% misdiagnosis rate, 40% malpractice win rate, $400k avg. indemnity payment)
Annual U.S. missed/delayed MI detection rate (Newman et al. 2022)
Experience the 12-Lead EXG™
Request a demo and see how we're revolutionizing cardiac monitoring